{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 82 of 129', '11.5.6 Aggravation of condition', 'Any clinically significant aggravation/exacerbation/worsening of any medical condition(s),', 'compared to screening, must be reported as an AE.', '11.6 Follow-up for final outcome of adverse events', 'During the trial, the investigator should follow up for final outcome on all AEs (including', 'SAEs). Once a subject leaves the clinical trial, the investigator should follow up on the', 'outcome of all non-serious AEs classified as of possible/probable relationship to the IMP for', '2 weeks or until the final outcome is determined, whichever comes first. SAEs must be', 'followed up until a final outcome has been established, i.e. the follow-up may continue', 'beyond the end of the clinical trial. For SAEs, which have stabilised and cannot be expected', 'to recover during trial or safety follow-up periods, for example chronic illnesses, the final', 'outcome should be considered recovered and a statement that the SAE has stabilised should', 'be added to the narrative in the SAE form.', '11.7 Handling of an urgent safety measure', 'An urgent safety measure is a measure taken to implement an action/protocol deviation under', 'an emergency. This is defined within the EU Directive as the occurrence of any new event', 'relating to the conduct of the trial or the development of the investigational medicinal product', 'where that new event is likely to affect the safety of the subjects, the sponsor and the', 'investigator shall take appropriate urgent safety measures to protect the subjects against any', 'immediate hazard.\" (34).', 'If the investigator becomes aware of information that necessitates an immediate change in the', 'clinical trial procedure or a temporary halt to the clinical trial in order to protect clinical trial', 'subjects from any immediate hazard to their health and safety, the investigator can do so', 'without prior approval from LEO, regulatory authority(ies), or IRB(s)/IEC(s).', 'The investigator must immediately inform LEO - by contacting the clinical project manager', 'or medical expert - of this change in the clinical trial procedure or of the temporary halt', 'providing full details of the information and the decision-making process leading to the', 'implementation of the urgent safety measure.', 'LEO must act immediately upon receipt of the urgent safety measure notification in', 'accordance with internal procedures and local legislation.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 83 of 129', '12 Statistical methods', '12.1 Sample size', 'A total of 369 subjects will be randomised 2:1 to initial treatment in this trial (246 subjects in', 'the tralokinumab+TCS arm; 123 subjects in the placebo+TC: arm).', 'The primary endpoints for initial treatment, IGA 0/1 and EASI75 at Week 16, are to be', 'evaluated hierarchically testing both hypotheses of no difference between active and placebo', 'at the 5% significance level. The hypothesis for IGA 0/1 will be tested first; if significant, the', 'EASI75 hypothesis will be tested.', 'The null hypothesis for the first primary endpoint is that there is no difference at Week 16 in', 'obtaining IGA 0/1 between tralokinumab+TC and placebo+TCS The null hypothesis for the', 'second primary endpoint is that there is no difference at Week 16 in obtaining EASI75', 'between tralokinumab+TC and placebo+TCS. Each hypothesis will be tested against the', '2-sided alternative that there is a difference between the 2 treatment groups.', 'For the single endpoint IGA 0/1 at Week 16, a sample size of 369 subjects randomised 2:1', 'will provide 90% power to detect a difference between the 2 arms, assuming response rates of', '30% for tralokinumab+TCS and 15% for placebo+TCS For the single endpoint EASI75 at', 'Week 16, a sample size of 369 will provide a nominal power >99.9% to detect a difference', 'between tralokinumab+TCS and placebo+TCS, assuming EASI75 response rates of 40% and', '15%, respectively. The combined power for demonstrating a significant difference for both', 'endpoints is therefore effectively also 90% with a sample size of 369 subjects, even when', 'assuming no correlation between the 2 primary endpoints. In all cases, the evaluations will be', 'made with a 2-sided 5% significance level.', '12.2 Trial analysis sets', 'All screened subjects will be accounted for in the CTR.', 'All subjects randomised to initial treatment are included in the full analysis set and will be', 'analysed for efficacy up to Week 16. Exclusions from the full analysis set can be considered', 'in special cases as described in ICH E9, Section 5.2.1, Full Analysis Set. If it is decided to', 'exclude a randomised subject from the full analysis set, a justification addressing ICH E9 will', 'be given.', 'A per protocol analysis set will be used as an efficacy subset for the analysis of the primary', 'endpoints up to Week 16, and analyses based on the per protocol analysis set will be', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}